Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Invivyd Inc. (IVVD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: IVVD (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $4.93
Year Target Price $4.93
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 117.11% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.15M USD | Price to earnings Ratio - | 1Y Target Price 4.93 |
Price to earnings Ratio - | 1Y Target Price 4.93 | ||
Volume (30-day avg) - | Beta 0.64 | 52 Weeks Range 0.35 - 2.74 | Updated Date 06/29/2025 |
52 Weeks Range 0.35 - 2.74 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -149.7% |
Management Effectiveness
Return on Assets (TTM) -57.84% | Return on Equity (TTM) -122.69% |
Valuation
Trailing PE - | Forward PE 4.91 | Enterprise Value 41479503 | Price to Sales(TTM) 2.38 |
Enterprise Value 41479503 | Price to Sales(TTM) 2.38 | ||
Enterprise Value to Revenue 1.13 | Enterprise Value to EBITDA 0.78 | Shares Outstanding 119961000 | Shares Floating 49770804 |
Shares Outstanding 119961000 | Shares Floating 49770804 | ||
Percent Insiders 41.18 | Percent Institutions 65.89 |
Analyst Ratings
Rating 4 | Target Price 4.93 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Invivyd Inc.
Company Overview
History and Background
Invivyd Inc., formerly Adagio Therapeutics, is a biopharmaceutical company focused on developing and commercializing antibody-based therapies for infectious diseases. Founded in 2020, the company has shifted its focus to address evolving viral threats, particularly those affecting vulnerable populations.
Core Business Areas
- Monoclonal Antibody Development: Development of novel monoclonal antibody therapies targeting SARS-CoV-2 and other respiratory viruses.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its antibody candidates.
Leadership and Structure
Invivyd is led by a management team with experience in biopharmaceutical development and commercialization. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Vixivirevimab (formerly ADG20): An investigational monoclonal antibody designed to neutralize SARS-CoV-2 variants. The future revenue will depend on clinical trial results, regulatory approval and market uptake. The key competitors are the developers of other monoclonal antibody and antiviral therapies for COVID-19, such as Regeneron and Gilead.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and stringent regulatory oversight. The market for infectious disease therapies is driven by the emergence of new pathogens and the need for effective treatments.
Positioning
Invivyd is positioned as a developer of novel antibody therapies targeting infectious diseases. Its competitive advantage lies in its ability to rapidly identify and develop antibodies against emerging viral threats.
Total Addressable Market (TAM)
The TAM for COVID-19 therapeutics is estimated to be in the billions of dollars, fluctuating with pandemic trends. Invivyd aims to capture a portion of this market with effective variant-neutralizing antibodies.
Upturn SWOT Analysis
Strengths
- Novel antibody platform
- Experienced management team
- Focus on emerging viral threats
- Potential for rapid antibody development
Weaknesses
- Limited product pipeline
- Reliance on clinical trial success
- Dependence on regulatory approvals
- Uncertainty in market demand for COVID-19 therapies
Opportunities
- Expanding the antibody platform to other infectious diseases
- Partnering with larger pharmaceutical companies
- Securing government funding for research and development
- Addressing unmet medical needs in vulnerable populations
Threats
- Competition from established pharmaceutical companies
- Failure to obtain regulatory approvals
- Emergence of new SARS-CoV-2 variants
- Changes in government healthcare policies
Competitors and Market Share
Key Competitors
- REGN
- GILD
- MRNA
- PFE
Competitive Landscape
Invivyd faces significant competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its ability to compete depends on the differentiated profile of its antibody candidates and its ability to execute its clinical development and commercialization strategy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development milestones and clinical trial progress rather than revenue generation.
Future Projections: Future growth depends on the successful development and commercialization of its antibody candidates. Analyst estimates vary based on clinical trial outcomes and regulatory prospects.
Recent Initiatives: Recent initiatives include advancing its antibody candidates through clinical trials, expanding its research and development efforts, and seeking partnerships with other organizations.
Summary
Invivyd is a clinical-stage biopharmaceutical company focused on developing antibody therapies for infectious diseases. The company's success hinges on the outcome of its clinical trials and regulatory approvals. While its novel antibody platform presents an opportunity, it faces intense competition and financial risks. Further clinical validation and strategic partnerships will be crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual risk tolerance and a thorough understanding of the company's business and financial condition. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Invivyd Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-08-06 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 99 | Website https://invivyd.com |
Full time employees 99 | Website https://invivyd.com | ||
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.